Xiaohui Chen

Fujian Medical University - Department of Thoracic Surgery

SCHOLARLY PAPERS

2

DOWNLOADS

121

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

CD8+ T Cell/Cancer-Associated Fibroblasts Ratio Stratifies Prognostic and Predictive Responses to Immunotherapy Across Multiple Cancer Types

Number of pages: 37 Posted: 20 Jun 2022
Fujian Medical University - Department of Thoracic Oncology, Fujian Medical University - Department of Thoracic Oncology, Fujian Medical University - Department of Pathology, Southern Medical University, Yunnan Cancer Hospital - The Second Department of Oncology, Geneplus Beijing Institute, Fujian Medical University - Department of Thoracic Surgery, Geneplus-Beijing Institute, Fujian Medical University - Department of Thoracic Oncology, Fujian Medical University - Department of Thoracic Oncology, Fujian Medical University - Department of Thoracic Oncology, Fujian Medical University - Department of Thoracic Oncology, Fujian Medical University - Department of Thoracic Oncology, Fujian Medical University - Department of Thoracic Oncology, Fujian Medical University - Department of Thoracic Oncology, Fujian Medical University - Department of Pathology, Geneplus-Beijing Co. Ltd., Geneplus Beijing Institute, Chinese People's Liberation Army - 92403 Unit Support Department Navy Fujian Base Hospital, National Center for Protein Sciences, Jiangsu University - Department of Medical Oncology, Geneplus Beijing Institute, Geneplus-Beijing Co. Ltd., Fujian Medical University - Department of Thoracic Oncology, Fujian Medical University - Department of Thoracic Oncology, Fujian Medical University - Laboratory of Biochemistry and Molecular Biology Research, Fujian Medical University - Department of Radiation Oncology and Fujian Medical University - Department of Thoracic Oncology
Downloads 64 (747,561)

Abstract:

Loading...

CD8+ T cell; cancer-associated fibroblast; prognostic biomarker; predictive biomarker; immunotherapy

2.

Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial

Number of pages: 19 Posted: 05 Feb 2024
Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Fujian Medical University - Fujian Medical University Cancer Hospital, Tongji University - Department of Oncology, Tongji University - Shanghai Pulmonary Hospital, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Fujian Medical University - Department of Thoracic Surgery, Tongji University - Department of Medical Oncology and Tongji University - Department of Medical Oncology
Downloads 57 (792,919)

Abstract:

Loading...

Camrelizumab, Nab-paclitaxel, Immunotherapy, ES-SCLC